Phase 1 clinical trial of KT-1002
Latest Information Update: 17 Oct 2019
At a glance
- Drugs KT 1002 (Primary)
- Indications Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions
- 17 Oct 2019 New trial record
- 20 Feb 2019 According to a Koutif Therapeutics media release, investigational new drug (IND) application for KT-1002 has been cleared by the US Food and Drug Administration to begin a Phase 1 clinical trial